Foundayo (Orforglipron): Eli Lilly's Weight Loss Pill — Price, Dosing and Results (2026)
Foundayo (orforglipron) is the first non-peptide oral GLP-1: a once-daily tablet with no empty-stomach rule, approved as Foundayo on April 1, 2026 and sold from $149/month cash ($299 at the maintenance doses). Here is what it does, what it costs, how it is dosed and how it compares with the Wegovy pill and the injectables. FDA approval announcement. Price records below retain their separately stated source-check dates.
What Is Foundayo?
Foundayo is the brand name of orforglipron, Eli Lilly's once-daily oral GLP-1 pill, FDA-approved on April 1, 2026 for chronic weight management and shipping from LillyDirect since April 6, 2026 from $149/month cash. In the ATTAIN-1 trial its top 17.2 mg dose produced 12.4% average weight loss over 72 weeks (about 27 lbs) against 0.9% on placebo, and it is the only GLP-1 pill with no food or water restrictions. Among pills that is second only to the Wegovy pill (13.6% in OASIS 4), and it is the only one with no fasting rule; the injectables still lose more. Medicare's GLP-1 Bridge (July 1, 2026 to December 31, 2027) covers it at $50/month for eligible Part D enrollees. FDA approval source. The Bridge operates outside the ordinary Part D benefit; eligibility is not automatic. CMS Bridge explanation.
Foundayo at a Glance
Orforglipron is a once-daily oral, small-molecule GLP-1 receptor agonist. Because it is not a peptide, it survives stomach acid without a special formulation, which means no fasting requirement, no restriction on food or water, and no absorption window. That is its fundamental advantage over oral semaglutide (Rybelsus and the Wegovy pill), which must be taken on an empty stomach with a 30-minute wait before eating or drinking.
What Is Orforglipron? A New Kind of GLP-1
Every other GLP-1 drug on the market, semaglutide (Ozempic, Wegovy, Rybelsus), liraglutide (Saxenda) and tirzepatide (Mounjaro, Zepbound), is a peptide: a chain of amino acids that mimics the natural GLP-1 hormone. Peptides work well, and they are fragile. Stomach acid destroys them, which is why most GLP-1 drugs are injections.
Oral semaglutide solved the problem partially by pairing semaglutide with an absorption enhancer (SNAC) that shields it from stomach acid. That is what creates the well-known rules: a completely empty stomach, no more than four ounces of plain water, then at least 30 minutes before eating, drinking or taking other medication. Many patients find the routine hard to keep, and only about 1% of the dose is absorbed.
Orforglipron takes a different approach. It is a small molecule, closer in kind to ibuprofen or metformin than to a peptide, so it is stable in the digestive system, absorbs regardless of food, and is made by standard chemical synthesis rather than biological manufacturing. Lilly's $149 cash price reflects that manufacturing advantage as much as its competitive positioning against compounded GLP-1s.
How Orforglipron Differs from Oral Semaglutide
| Feature | Orforglipron (Foundayo) | Oral semaglutide (Wegovy pill, Rybelsus) |
|---|---|---|
| Molecule type | Non-peptide small molecule | Peptide + SNAC enhancer |
| Empty stomach required? | No | Yes (30-minute wait) |
| Water restriction? | No | Yes (4 oz max) |
| Weight-loss indication | Approved April 1, 2026 | Wegovy pill approved Dec 22, 2025; Rybelsus diabetes only |
| Pivotal weight-loss result | 12.4% at 72 wk (ATTAIN-1) | 13.6% at 64 wk (Wegovy pill, OASIS 4) |
| Self-pay price | $149–$299/mo by dose | Wegovy pill $149–$299/mo by dose; Rybelsus $1,028 list |
| Manufacturing | Standard chemical synthesis | Biological peptide manufacturing |
Phase 3 Trial Results: What the Data Shows
ATTAIN-1: Obesity Without Diabetes
Adults with obesity on the highest 17.2 mg dose who stayed on treatment lost an average of 12.4% of body weight (about 27 lbs) over 72 weeks, against 0.9% on placebo, and 51.5% of women reached 15% or more. The trial met its primary and key secondary endpoints and is the basis of the weight-management approval.
ATTAIN-2: Type 2 Diabetes
In adults with obesity or overweight and type 2 diabetes, the highest dose delivered 10.5% average weight loss (22.9 lbs) with A1C reductions averaging 1.8 points. Both primary and key secondary endpoints were met; the diabetes indication itself is not yet approved.
ATTAIN-MAINTAIN: Switching from Injectables
This first-of-its-kind trial asked whether patients could switch from injectable semaglutide or tirzepatide to orforglipron and keep their weight off. All three doses met the primary and key secondary endpoints at 72 weeks, with weight maintenance, A1C reductions and improved cardiometabolic markers. Starting on an injection and moving to the pill is therefore a studied path, not a guess.
FDA Approval and Availability
The FDA approved orforglipron as Foundayo on April 1, 2026, one of the fastest approvals since 2002 under Priority Review and a Commissioner's National Priority Voucher, for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. LillyDirect, Lilly's own online pharmacy, began shipping on April 6, 2026. It is the first oral non-peptide GLP-1 approved for any indication; a type 2 diabetes submission is separate and still pending. FDA approval announcement.
How Much Does Foundayo Cost? Price by Dose
Foundayo costs $149–$299/month cash through LillyDirect depending on dose, $50/month for eligible Medicare beneficiaries under the GLP-1 Bridge, and about $25/month with Lilly's savings card when a commercial plan covers weight-loss drugs. The cash price is tiered by dose: $149 at the 0.8 mg and 2.5 mg starting doses, $199 at 5.5 mg and $299 from 9 mg up. The 14.5 mg and 17.2 mg price is Lilly's Self-Pay Journey Program rate and needs a refill within 45 days (regular prices apply otherwise), and the 2.5 mg and 5.5 mg prices are reduced through December 31, 2026. Even the $299 maintenance price undercuts every injectable brand (the self-pay Wegovy pen is $349/month and Zepbound runs $299–$449/month by dose on LillyDirect, $1,086 at list), and it matches the Wegovy pill's $149-to-$299 ladder exactly.
| Dose | Self-pay / month | Condition |
|---|---|---|
| 0.8 mg | $149 | Starting dose |
| 2.5 mg | $149 | Temporarily reduced through Dec 31, 2026 |
| 5.5 mg | $199 | Temporarily reduced through Dec 31, 2026 |
| 9 mg | $299 | Standard self-pay price |
| 14.5 mg | $299 | Self-Pay Journey Program price; needs a refill within 45 days |
| 17.2 mg | $299 | Self-Pay Journey Program price; needs a refill within 45 days |
| Medicare GLP-1 Bridge | $50 | Eligible Part D enrollees, July 1, 2026 to Dec 31, 2027 |
| Commercial plan that covers it | as low as $25 | Lilly savings card; terms apply |
- Cash, no insurance: $149/month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, $299 at 9, 14.5 and 17.2 mg via LillyDirect (30-day supply). The 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026, per LillyDirect.
- Medicare: $50/month under the Medicare GLP-1 Bridge, which launched July 1, 2026 and runs through December 31, 2027. The CMS fact sheet lists Foundayo (tablet) alongside Wegovy and Zepbound KwikPen; it excludes people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease (their Part D plan may already cover a GLP-1) and requires a BMI of 35+, or a lower BMI with specific conditions.
- Commercial insurance: roughly $25/month with the savings card where weight-loss drugs are covered; coverage is still uneven.
- Through telehealth platforms: the $149–$299 medication price plus the platform's membership or provider fee (Sesame Care $59/month on a 12-month commitment, Shed, formerly ShedRx, $125/month, Hers and Hims $149/month), so budget about $208–$448 all-in depending on dose and platform. Who lists it is below.
- Against compounded GLP-1s: compounded semaglutide injections start at $79/month and tirzepatide at $129/month among the providers we track (Price Index snapshot November 11, 2026); they are cheaper, but they are injections and not FDA-approved finished products; brand tirzepatide (Zepbound) lost more in its trial, and compounded versions have no trial of their own.
Full paths and the LillyDirect flow are in our Foundayo cost breakdown.
How to Get Foundayo
Foundayo needs a prescription. The direct route is LillyDirect (from $149/month self-pay); Medicare enrollees who qualify fill it at a pharmacy for $50 under the Bridge; and 5 of the telehealth providers we track list it on their menu.
- Your own doctor or a telehealth clinician writes the prescription (BMI 30+, or 27+ with a weight-related condition).
- Pay route: LillyDirect self-pay ($149–$299 by dose), Medicare GLP-1 Bridge ($50), or a commercial plan with Lilly's savings card (as low as $25).
- Start at 0.8 mg for at least 30 days, then step up as tolerated (schedule below).
Provider records that list Foundayo (5 of the 52 in the directory): ShedRx, Sesame Care, Hers, Hims, Found.
We earn a commission when you sign up with an affiliate partner through our links.
Foundayo Dosage Schedule
Everyone starts at 0.8 mg once daily for at least 30 days, then 2.5 mg for at least 30 days, then 5.5 mg; from there the dose can rise to 9 mg, 14.5 mg or the 17.2 mg maximum, each step after at least 30 days and only as tolerated. The starter dose is there to build gastrointestinal tolerance, not to drive weight loss, and prescribers stop at the lowest dose that produces sustainable results. Take it once a day at any time, with or without food or water; a missed dose is taken the same day if remembered, otherwise skipped, never doubled.
Full titration detail in our Foundayo dosage schedule.
How Orforglipron Compares to the Other Options
| Drug | Delivery | Targets | Pivotal weight loss | Self-pay / mo | Status |
|---|---|---|---|---|---|
| Orforglipron (Foundayo) | Daily pill, no fasting | GLP-1 | 12.4% (ATTAIN-1, 72 wk) | $149–$299 | Approved April 1, 2026 |
| Wegovy pill (oral semaglutide) | Daily pill, fasting rule | GLP-1 | 13.6% (OASIS 4, 64 wk) | $149–$299 by dose | Approved Dec 22, 2025 |
| Wegovy (semaglutide injection) | Weekly injection | GLP-1 | 14.9% (STEP 1, 68 wk) | $349 ($199 intro) | Approved |
| Zepbound (tirzepatide) | Weekly injection | GLP-1 + GIP | 20.9% (SURMOUNT-1, 72 wk) | $299–$449 vials (LillyDirect); $1,086 list | Approved |
| Rybelsus (oral semaglutide) | Daily pill, fasting rule | GLP-1 | about 3–5% (PIONEER) | $1,028 list | Approved, diabetes only |
| Retatrutide | Weekly injection | GLP-1 + GIP + glucagon | up to ~28.7% (phase 3) | — | Not approved |
Trial results are the published averages at the highest doses and stated durations; no head-to-head trial exists between these products. Compounded semaglutide and tirzepatide injections from tracked providers start at $79 and $129/month.
Safety and Side Effects
Orforglipron's side effects are the familiar GLP-1 class effects, mostly gastrointestinal and mostly early: nausea, diarrhea, constipation, vomiting and reduced appetite, worst in the first weeks after each dose increase. That pattern is why the titration is gradual, and the management playbook matches the injectables: smaller, lower-fat meals, hydration, and holding a dose step longer rather than pushing through.
Like every GLP-1 it carries the class boxed warning about thyroid C-cell tumours seen in rodent studies, and it should not be used with a personal or family history of medullary thyroid carcinoma or MEN 2. Pancreatitis, gallbladder problems and severe allergic reactions are rare but warrant stopping and calling your prescriber. One practical advantage of daily dosing: dose adjustments are more granular than with a weekly injection, which lets prescribers titrate more carefully around side effects.
Foundayo (Orforglipron): Frequently Asked Questions
What is Foundayo?
Foundayo is the brand name of orforglipron, Eli Lilly's once-daily GLP-1 pill for chronic weight management. The FDA approved it on April 1, 2026 for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related condition, and LillyDirect has shipped it since April 6, 2026. It is a small molecule rather than a peptide, so unlike the Wegovy pill it can be taken at any time, with or without food or water. In the ATTAIN-1 trial the top 17.2 mg dose produced 12.4% average weight loss over 72 weeks.
Is Foundayo covered by Medicare?
Yes, through the Medicare GLP-1 Bridge, which began July 1, 2026 and runs through December 31, 2027. The CMS fact sheet lists Foundayo (tablet), Wegovy and Zepbound KwikPen at $50 per month. You need Part D coverage, must not already get a GLP-1 through your drug plan, must not have type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease, and must be 18+ with a BMI of 35+, or 30+ with certain heart failure, hard-to-control high blood pressure or stage 3a+ kidney disease, or 27+ with prediabetes or a prior heart attack, stroke or blocked arteries. The $50 does not count toward your Part D deductible or out-of-pocket limit.
Is orforglipron available now?
Yes. The FDA approved orforglipron under the brand name Foundayo on April 1, 2026 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with a weight-related condition, and Eli Lilly's LillyDirect pharmacy began shipping it on April 6, 2026. It is a prescription medication, so you need a prescriber; LillyDirect and a growing number of telehealth platforms can arrange the consultation and fulfilment.
How much does Foundayo cost?
Foundayo (orforglipron) costs $149–$299/month cash through LillyDirect depending on dose ($149 at the 0.8 mg and 2.5 mg starting doses, $199 at 5.5 mg, $299 from 9 mg up), which is 72–86% below the $1,086 list price of Lilly's own injectable Zepbound. Eligible Medicare beneficiaries pay $50/month under the Medicare GLP-1 Bridge, and commercially insured patients whose plan covers weight-loss drugs pay about $25/month with Lilly's savings card. The 14.5 mg and 17.2 mg price is Lilly's Self-Pay Journey Program rate and applies only if you refill within 45 days; the 2.5 mg and 5.5 mg prices are temporarily reduced through December 31, 2026 (LillyDirect, read October 5, 2026). Telehealth platforms that prescribe it add their own membership or provider fee on top of the medication price.
Is orforglipron a pill or an injection?
Orforglipron is a once-daily oral tablet, not an injection. Because it is a small molecule rather than a peptide, it survives stomach acid without an absorption enhancer, so unlike oral semaglutide (Rybelsus and the Wegovy pill) it can be taken at any time of day, with or without food or water.
How much weight do people lose on orforglipron?
In the ATTAIN-1 phase 3 trial, adults with obesity on the highest 17.2 mg dose who stayed on treatment lost an average of 12.4% of their body weight (about 27 lbs) over 72 weeks, versus 0.9% on placebo, and 51.5% of women reached 15% or more. In ATTAIN-2, adults who also had type 2 diabetes lost 10.5% (22.9 lbs) with an average A1C reduction of 1.8 points. Among pills only the Wegovy pill did better, at 13.6% over 64 weeks in OASIS 4. The injectables lose more: 14.9% for Wegovy in STEP 1 and 20.9% for Zepbound in SURMOUNT-1.
How does orforglipron compare to Wegovy or Zepbound?
Orforglipron delivers less weight loss than the injectables (12.4% versus about 14.9% for Wegovy and 20.9% for Zepbound) but wins on convenience and cash price: a daily pill with no injection and no fasting rule at $149–$299/month by dose, against $349/month for the self-pay Wegovy pen and $299–$449/month for Zepbound vials on LillyDirect ($1,086 list). If needles are the dealbreaker it is the most convenient oral option; if they are not, a brand injectable usually gives more weight loss per dollar.
What is the orforglipron dosage schedule?
Everyone starts at 0.8 mg once daily for at least 30 days, then moves to 2.5 mg for at least 30 days and on to 5.5 mg; after that the dose can be raised to 9 mg, 14.5 mg or the 17.2 mg maximum, each after at least 30 days on the current dose and only as response and tolerability allow. The starter dose exists to build gastrointestinal tolerance rather than to drive weight loss, and not everyone needs to reach the maximum; prescribers settle on the lowest dose that produces sustainable results.
Can I switch from an injectable GLP-1 to orforglipron?
The ATTAIN-MAINTAIN trial studied exactly this: patients who had lost weight on injectable semaglutide or tirzepatide switched to orforglipron and maintained their weight loss at 72 weeks on all three doses tested. Starting on an injectable and transitioning to the daily pill is therefore a studied strategy, but the switch must be managed by your prescriber.
Is orforglipron the same as oral Ozempic?
No. Orforglipron is a different molecule from semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus. Semaglutide is a peptide that needs the SNAC absorption enhancer to survive the stomach in pill form; orforglipron is a non-peptide small molecule that absorbs on its own. Both activate the GLP-1 receptor, but their structure, manufacturing and dosing rules are different.
Does orforglipron work for type 2 diabetes?
ATTAIN-2 showed an average A1C reduction of 1.8 points and 10.5% weight loss in people with type 2 diabetes, but the April 1, 2026 approval covers chronic weight management only. A diabetes indication would need a separate FDA decision; prescribing Foundayo for glucose control in the meantime is off-label.
Pill or Injection? Compare Your Options
Foundayo is the only GLP-1 pill with no fasting rule, from $149/month ($299 at the maintenance doses). If you are open to a weekly injection, listed compounded programs start lower, and brand Zepbound lost more in its trial — compare every tracked provider before you decide.